Ivan Hyep, Chief Financial Officer of Bicara Therapeutics Inc. (NASDAQ:BCAX), filed a Form 4 on August 12, 2026, disclosing the exercise of stock options and the sale of 12,500 shares of common stock on August 10, 2026, pursuant to a Rule 10b5-1 trading plan.

Key Highlights

  • Option exercise: Ivan Hyep acquired 12,500 shares of common stock via a stock option exercise at a price of $3.7898 per share on August 10, 2026.
  • Shares sold: 12,500 shares were disposed of at a weighted average price of $27.9673, with individual transaction prices ranging from $27.675 to $28.185, inclusive.
  • Beneficial ownership after transactions: Hyep directly holds 129,855 shares of common stock following the reported transactions.
  • 10b5-1 plan: Both the option exercise and the sale were executed pursuant to a Rule 10b5-1 trading plan adopted on March 31, 2026.
  • Remaining options: Hyep retains 26,336 stock options with an exercise price of $3.7898 expiring April 5, 2033, held directly.

Details of Ivan Hyep's August 2026 Transactions at Bicara Therapeutics

According to the filing, Ivan Hyep, serving as Chief Financial Officer of Bicara Therapeutics Inc., executed two transactions on August 10, 2026. First, he acquired 12,500 shares of common stock through the exercise of a stock option at $3.7898 per share, coded as an "M" transaction. Immediately following that exercise, his total direct beneficial ownership stood at 142,355 shares, the filing disclosed.

Hyep then sold those 12,500 shares in a transaction coded "S," at a weighted average price of $27.9673 per share. The filing noted that the shares "were sold in multiple transactions at prices ranging from $27.675 to $28.185, inclusive," and that Hyep undertakes to provide full details on shares sold at each individual price upon request. After this disposition, his direct beneficial ownership of common stock totaled 129,855 shares, according to the filing.

The filing identified both transactions as made pursuant to a Rule 10b5-1 trading plan that Hyep adopted on March 31, 2026. The underlying stock option, which carried an exercise price of $3.7898 and an expiration date of April 5, 2033, was described as vesting "in sixteen equal quarterly installments following April 5, 2023, subject to the Reporting Person's continued service on each such vesting date." Following the partial exercise, 26,336 options remain beneficially owned directly by Hyep, according to the filing. The Form 4 was signed by Ryan Cohlhepp as Attorney-in-Fact on August 12, 2026.

What Was Disclosed

Bicara Therapeutics CFO Ivan Hyep disclosed the exercise of 12,500 stock options at $3.7898 per share and the same-day sale of those shares at a weighted average price of $27.9673, both executed under a pre-established Rule 10b5-1 plan, leaving him with 129,855 shares held directly.